SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EARNINGS FLASH L impact

Newbury Pharmaceuticals (NEWBRY) FY26 Revenue SEK 42.7M, EBITDA -SEK 18.3M

Newbury Pharmaceuticals reported FY26 net revenue of SEK 42.7M (SEK 31.6M) and EBITDA of -SEK 18.3M (SEK -16.3M). Q4 revenue was SEK 13.6M vs SEK 5.9M; gross margin fell to ~25% from 41%.Material DetailsContext by AI AnalystThis is a mid-cycle update: strong Nordic-led growth but profitability lags…

NEWBRY
SquawkNews Desk

Related stories

Hotman Reports Interim Operating Loss Hotman reported a standalone interim operating loss, compared with an operating loss in the same period a year earlier. Its fiscal-year forecast calls for operating profit, up 7.9% M impact | EARNINGS | Oct 30, 2026, 02:00 AM UTC Hotman Reports Six-Month Parent Net Loss Hotman reported a parent net loss compared with a larger loss a year earlier. It forecasts a profit for 2026/27, up 3.7%. M impact | EARNINGS | Oct 30, 2026, 02:00 AM UTC Tokai Tokyo Financial Holdings Reports Six-Month Group Recurring Profit Up 82.4% Group recurring profit increased 82.4% over the six-month period. M impact | EARNINGS | Oct 30, 2026, 02:00 AM UTC Tokai Tokyo Financial Holdings Group Net Profit Rises 58% in Six Months M impact | EARNINGS | Oct 30, 2026, 02:00 AM UTC Tokai Tokyo Financial Holdings reports interim net profit of 101.65億円, up 58.0% Tokai Tokyo Financial Holdings reported consolidated net profit of 101.65億円 for the interim period ended September, up 58.0%. M impact | EARNINGS | Oct 30, 2026, 02:00 AM UTC Tokai Tokyo Financial Holdings Reports 6-Month Group Operating Profit Up 77.0% M impact | EARNINGS | Oct 30, 2026, 02:00 AM UTC